Megan Hollasch

Articles

O’Shaughnessy Showcases Highlights in Breast Cancer Guiding 2023 IBC Congresses

April 21st 2023

Joyce A. O’Shaughnessy, MD, highlights multidisciplinary approaches including discussions on tumor boards, and discusses how to better assist patients with accessing care, and notable advances in the field particularly with the HER2 classification.

Oncology Financial Navigator Interventions Provide Benefits to Patients With Hematologic Cancers

April 20th 2023

To evaluate the prevalence of financial toxicity and observe the effect of Coverage and Cost-of-Care Links, a program providing financial navigation, investigators initiated a nonrandomized study.

IO-108 Demonstrates Safety and Efficacy in Advanced Solid Tumors

April 19th 2023

Findings from a phase 1 study showed that the fully humanized IgG4 antibody IO-108 was well tolerated and displayed durable responses when given as a monotherapy as well as in combination with pembrolizumab, supporting further development of the agent alone or with PD-1/PD-L1 targeted therapy for patients with advanced solid tumors.

Divarasib Plus Cetuximab Demonstrates Promising Clinical Activity and Manageable Safety in KRAS G12C–Mutant CRC

April 18th 2023

The selective, oral KRASG12C inhibitor divarasib demonstrated promising clinical activity in patients with colorectal cancer treated with the agent plus cetuximab.

Pembrolizumab Yields High Response Rates for Patients With Unresectable Metastatic Desmoplastic Melanoma

April 17th 2023

Patients with unresectable metastatic desmoplastic melanoma achieved high response rates when treated with single-agent pembrolizumab in the SWOG S1512 trial, according to data presented during the 2023 AACR Annual Meeting.

Eskander Highlights PFS Outcomes With Pembrolizumab in dMMR/pMMR Advanced Endometrial Cancer

April 12th 2023

Ramez N. Eskander, MD, highlights the potential implications of the NRG GY018 trial as well as safety and efficacy results from the trial.

Nuances in SORAYA Data Highlight Role of Mirvetuximab Soravtansine in FRα-High Platinum-Resistant Ovarian Cancer

April 7th 2023

Robert L. Coleman, MD, FACOG, FACS, discusses a subgroup analysis of the SORAYA trial, which was presented during the 2023 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, and where the field is headed in attempt to address unmet needs for this patient population.

Dostarlimab Plus Chemotherapy Shows Survival Benefit, Fills Unmet Need for Patients With Recurrent Endometrial Cancer

April 6th 2023

Combining the immune checkpoint inhibitor dostarlimab-gxly with standard-of-care chemotherapy elicited an increase in progression-free survival rates compared with chemotherapy alone for patients with primary advanced or recurrent endometrial cancer.

Delays in Cancer Screenings Due to COVID-19 May Result in Trend Toward Excess Deaths

March 24th 2023

Cancer screenings rapidly decreased during the COVID-19 pandemic as health care practices considered not urgent came to a halt.

Adjuvant Pembrolizumab Expands Options for Patients with Resected Stage IB-IIIA NSCLC

March 21st 2023

Luis Paz-Ares, MD, PhD, highlight adverse events to monitor with pembrolizumab in this setting as well as its role in the treatment landscape.

Dostarlimab Fills Unmet Need for Patients with dMMR Advanced Endometrial Cancer

March 20th 2023

Lucy Gilbert, MD, MSc, discusses the favorable safety profile of dostarlimab as well as how it compares with the current standard of care in mismatch repair deficient advanced endometrial cancer.

Response-Guided Therapy Is the Next Frontier for Tailoring Therapy in HER2+ Breast Cancer

March 10th 2023

Lisa M. Carey, MD, ScM, FASCO, discusses upcoming treatments that could impact standard-of-care practices and the continually evolving role of antibody-drug conjugates role in the breast cancer treatment paradigm.

Palbociclib Plus Aromatase Inhibitor Therapy Provides Real-World Benefit in Older Patients With HR+/HER2– Metastatic Breast Cancer

March 7th 2023

Palbociclib plus an aromatase inhibitor improved real-world data for progression-free survival, overall survival, and time to chemotherapy compared with an aromatase inhibitor alone in patients 75 years and older with hormone receptor–positive, HER2-negative advanced/metastatic breast cancer.

ADCs Advance HR+/HER2– Breast Cancer Treatment Paradigm

March 7th 2023

As more antibody-drug conjugates emerge and investigators foresee fam-trastuzumab deruxtecan-nxki moving forward in lines of treatment for metastatic disease, the treatment landscape of hormone receptor–positive, HER2-negative breast cancer continues to expand and shift.

Wang Details Caveats to Standards of Care for Treating Patients With MCL

February 28th 2023

When treating patients with mantle cell lymphoma, early identification and appropriate frontline therapy remains critical, and therapies may vary for those 65 years and older compared with patients under the age of 65, with several additional factors also having a role in approaching treatment options for a new patient in the clinic.

Triplet Regimen for Microsatellite Stable, BRAF V600E–Mutant mCRC Aims to Build Upon SOC

February 27th 2023

Because a positive correlation has been shown between expression of PD-L1 and BRAF V600E mutations in CRC, several combination therapies with checkpoint inhibitors and targeted agents are currently being explored.

Lenvatinib Plus Pembrolizumab Generates Durable Responses in Advanced Endometrial Carcinoma

February 26th 2023

Lenvatinib in combination with pembrolizumab led to deep and durable tumor responses in patients with previously treated advanced endometrial carcinoma.

New Technology Advances Prostate Cancer Care But Questions Linger

February 21st 2023

Phillip J. Koo, MD, highlights insights garnered from prostate cancer experts on topics such as radioligands and modern radiopharmaceuticals, which, along with artificial intelligence, have the potential to revolutionize the field.

Elacestrant Secures a Place for ER+, HER2–, ESR1-Mutated Advanced/Metastatic Breast Cancer

February 15th 2023

François-Clément Bidard, MD, PhD, discusses how elacestrant fits into the treatment paradigm for postmenopausal patients with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

Teclistamab Demonstrates Exciting Efficacy in Relapsed or Refractory Multiple Myeloma

February 9th 2023

Alfred L. Garfall, MD, discusses the durability of responses teclistamab elicited in the MajesTEC-1 trial and how this agent will change the treatment regimen for relapsed/refractory multiple myeloma.